Search

Search Constraints

You searched for: Author/Creator Sanfilippo, Roberta

Search Results

1. Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP‐1 and TIMP‐2 and tumor thrombospondin‐1. Issue 3 (19th June 2014)

2. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis. Issue 3 (16th December 2018)

3. Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149–168]. (February 2021)

4. Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Issue 5 (18th November 2020)

5. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Issue 11 (4th March 2020)

6. Health‐related quality‐of‐life results from PALETTE: A randomized, double‐blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Issue 17 (29th May 2015)

7. Health‐related quality‐of‐life results from PALETTE: A randomized, double‐blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Issue 17 (29th May 2015)

8. High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. (30th August 2017)

9. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). (November 2020)